NewsKanaVape Duo Back In Court As Appeal Judges Question...

KanaVape Duo Back In Court As Appeal Judges Question French Position On CBD

-

THE KanaVape case has returned to France and following a hearing yesterday at the Aix-en-Provence Court of Appeal a final judgement is due next month.

In January 2018, the businessmen behind KanaVape – Antonin Cohen and Sébastien Béguerie of SAS Catlab – were given a 16-month suspended sentence, and a €10,000 fine, by Marseilles Criminal Court.

Later that year, the Aix Appeal Court, 20 miles north of Mareseilles, overturned this first instance verdict, saying the ruling may not be compliant with the freedom of movement of goods of the European Union. 

The Luxembourg-based Court of Justice of the European Union (CJEU) was therefore tasked with answering whether cannabidiol (CBD) was a narcotic, and whether France could prohibit its importation from one of the member countries of Europe if it was produced legally.

CBD Not A Narcotic

In November, last year the CJEU ruled that CBD is not a narcotic, that a member state cannot restrict the free movement of CBD products and that CBD can be derived from the hemp flower. 

This was a snub for the MILDECA – the French Inter-ministerial Mission for Combating Drugs and Addictive Behaviours – which had interpreted the legal texts in a restricted manner.

Wednesday’s hearing was intended to clarify the various points on which the court will have to render its decision, namely:

the legality of the alleged French ban on CBD

the presentation of Kanavape as a ‘drug’ which had served as an argument for the Ministry of Health to stop the marketing of Kanavape in France

An incitement on the use of narcotics for clinical studies on cannabis

And the possession of cannabis

KanaVape.

The decision of the Aix Court of Appeal will be based on the judgment of the CJEU, although it does have the choice to waive it. Its final decision will be delivered on November 17.

Lawyers Xavier Pizarro, Éveline Van Keymeulen and Stéphane Pages represented Mr Beguerie and Mr Cohen. 

In a pre-hearing press release Mr Béguerie said: “It is high time that we were recognized as innovative entrepreneurs and not as drug traffickers in our own country. “

Mr Cohen now runs Harmony CBD based in Barcelona and Mr Béguerie is Co-Founder of Golden Buds and is looking to relaunch the brand as KanaVape2.0

The case stretches back to 2014 when the French authorities launched a legal action against the makers of KanaVape, which is an e-cigarette using a CBD oil made from hemp flowers imported from the Czech Republic.

In June this year France’s highest court ruled that CBD – including CBD flowers – are legal in the country, although there is still some uncertainty around the permissible level of THC, while the French government is currently considering measures to temper the CBD market.



LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest news

Thought Leaders Acquisition Of mellow Set To Accelerate Growth Across UK, Europe, And Asia Footprint

THE CBD world is set with a massive shake-up this week as Thought Leaders, the US cannabis & CBD investment company,...

Medical Cannabis Cost-Benefit Analysis Set To Be Launched By UK CIC At A Cost of £30,000

THE initial priorities of the UK Cannabis Industry Council have been identified following a special general meeting attended by...

CIC Research Group Looking To Overcome The ‘Scandalous’ Impasse On UK Medical Cannabis Prescribing

Chartered Psychologist and Head of Research at Drug Science, Dr Anne Katrin Schlag, heads up the newly formed Cannabis...

European Cannabis Market Leader Bloomwell Group Secures $10m Investment

The Bloomwell Group has successfully closed a seed funding round of over $10 million dollars—the highest publicly known seed investment...

German Hemp Farm Numbers Up 900% In Seven Years – As industry Calls For Post-Election Reform

THE number of German farms growing industrial hemp has hit 863 – the highest figure since the federal republic...

US Company Set To Launch UK Medical Cannabis Study In Partnership With Manchester University

A GROUND-BREAKING human pilot study centred on the University of Manchester could provide answers to using cannabis as a...

Must read

Medical Cannabis Cost-Benefit Analysis Set To Be Launched By UK CIC At A Cost of £30,000

THE initial priorities of the UK Cannabis Industry Council...

CIC Research Group Looking To Overcome The ‘Scandalous’ Impasse On UK Medical Cannabis Prescribing

Chartered Psychologist and Head of Research at Drug Science,...

You might also likeRELATED
Recommended to you